| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.INS - XBRL INSTANCE DOCUMENT | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| D |
Other
|
|||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
||
| SC 13G/A | An amendment to the SC 13G filing |
Other
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
